Lilly has announced its acquisition of Kelonia Therapeutics, a move aimed at enhancing its capabilities in in vivo CAR-T cell therapies. Kelonia’s lead candidate, KLN-1010, is a novel lentiviral in vivo CAR-T therapy currently in Phase 1 trials for relapsed/refractory multiple myeloma. The therapy leverages Kelonia’s proprietary in vivo gene placement system (iGPS®), which utilizes engineered lentiviral particles to facilitate the generation of CAR-T cells directly within the patient’s body, targeting the B-cell maturation antigen (BCMA) on myeloma cells.

This acquisition is significant as it positions Lilly to address the manufacturing and accessibility challenges that have historically limited the reach of CAR-T therapies. Current autologous CAR-T treatments have shown improved outcomes for cancer patients but face barriers that restrict their availability. Kelonia’s platform promises to deliver rapid and durable responses in a more streamlined, off-the-shelf format, potentially transforming how CAR-T therapies are deployed in clinical settings.

The implications of this acquisition extend beyond mere expansion of Lilly’s portfolio; it signals a shift in the research paradigm towards more accessible and efficient gene therapies. By integrating Kelonia’s innovative technology, Lilly aims to expedite the development timelines for CAR-T therapies, making them more widely available to patients in need. This strategic move could catalyze advancements in genetic medicine, ultimately enhancing treatment options for various cancers and improving patient outcomes in the long term.

Source: investor.lilly.com